

# Clinical Characteristics, Treatment Outcomes, and Prognostic Factors in Hodgkin Lymphoma: A Retrospective Cohort Study at King Khalid Hospital, Najran

Ahmed M. Badheeb<sup>1\*</sup>, Hasan Salem Al Greshah<sup>2</sup>, Musadag Elhadi<sup>3</sup>, Nasher H Alyami<sup>4</sup>, Abdelaziz Aman<sup>5</sup>, Islam A. Seada<sup>6</sup>, Abdullah Abu Bakar<sup>7</sup>, Samer Alkarak<sup>8</sup>, Mohammed S. Bazuqamah<sup>9</sup>, Mahran Mohammed<sup>10</sup>, Ammar Idris<sup>10</sup>, Faisal Ahmed<sup>11</sup>, Mohamed Badheeb<sup>12</sup>

<sup>1</sup>Oncology, King Khalid Hospital - Oncology Center, Najran, Saudi Arabia. <sup>2</sup>Hematology, King Khalid Hospital, Najran, Saudi Arabia. <sup>3</sup>Internal Medicine, King Khalid Hospital, Najran, Saudi Arabia. <sup>4</sup>Laboratory Medicine Department, Hematology Unit, Ministry of Health, Najran General Hospital, Najran, Saudi Arabia. <sup>5</sup>Internal Medicine, Endocrine and Diabetes, King Khalid Hospital, Najran, Saudi Arabia. <sup>6</sup>Cardiothoracic Surgery, King Khalid Hospital, Najran, Saudi Arabia. <sup>7</sup>Ophthalmology, King Khalid Hospital, Najran, Saudi Arabia. <sup>8</sup>General Surgery, King Khalid Hospital, Najran, Saudi Arabia. <sup>9</sup>Laboratory Medicine, King Khalid Hospital, Najran, Saudi Arabia. <sup>10</sup>Oncology, King Khalid Hospital, Najran, Saudi Arabia. <sup>11</sup>Urology, Ibb University, Ibb, Yemen. <sup>12</sup>Internal Medicine, Yale New Haven Health, Bridgeport Hospital, Bridgeport, USA.

## Abstract

**Introduction:** Hodgkin lymphoma (HL) is characterized by heterogeneous clinical outcomes influenced by a complex interplay of biological and clinical factors. This study aims to delineate presentation patterns, treatment responses, and prognostic indicators within a Saudi Arabian cohort, with consideration of regional epidemiological variations. **Materials and Methods:** A retrospective cohort study was conducted involving 23 patients diagnosed with HL at King Khalid Hospital, Najran, between 2014 and 2021. Diagnoses were established according to the World Health Organization (WHO) 2017 classification. Treatment responses were assessed after every two chemotherapy cycles using RECIST version 1.1, due to limited availability of PET imaging modalities. Progression-free survival (PFS) predictors were analyzed using univariate Cox proportional hazards regression, with explicit acknowledgment of the limited statistical precision stemming from the small sample size. **Results:** The mean age was  $36.3 \pm 16.3$  years, with males constituting 60.9% of the cohort. Nodular sclerosis was the most common histological subtype (65.2%), and stage III was the most frequent at diagnosis (43.5%). The ABVD chemotherapy regimen yielded an objective response rate of 78.3%, with a complete response observed in 43.5% of patients. At a median follow-up of 33 months, univariate analysis identified significant associations between reduced PFS and advanced disease stage (III/IV vs. I/II; hazard ratio [HR] 3.26, 95% confidence interval [CI] 0.34–31.35;  $p=0.001$ ), high International Prognostic Score (IPS  $\geq 3$  vs. 0–2; HR 17.93, 95% CI 1.85–173.94;  $p=0.013$ ), and increasing age (per year; HR 1.21, 95% CI 1.10–1.34;  $p<0.001$ ). **Conclusions:** In this cohort, advanced disease stage, elevated IPS, and increasing age were associated with inferior PFS, consistent with established prognostic models despite regional epidemiological differences. These findings underscore the necessity for larger, prospective studies to validate risk stratification tools and optimize management strategies in similar healthcare settings.

**Keywords:** Hodgkin lymphoma- progression-free survival- prognosis- ABVD chemotherapy- retrospective study

*Asian Pac J Cancer Care*, 11 (2), 169-177

Submission Date: 11/29/2025

Acceptance Date: 01/06/2026

## Introduction

Hodgkin lymphoma (HL) is a hematologic malignancy exhibiting marked clinical and biological heterogeneity, reflected in variable incidence patterns, prognostic factors,

and therapeutic outcomes across global populations [1, 2]. Therapeutic advances have improved 5-year survival rates to over 80% in high-income countries;

### Corresponding Author:

Dr. Ahmed M. Badheeb

Oncology, King Khalid Hospital - Oncology Center, Najran, Saudi Arabia.

Email: Badheebdr@gmail.com

however, significant geographical disparities persist, underscoring the need for region-specific data to optimize management strategies [3-5].

In Saudi Arabia, HL displays distinct epidemiological characteristics. The age-standardized incidence rate exceeds that of neighboring Gulf countries, with HL accounting for approximately 3.6% of all malignancies nationally [6, 7]. National cancer registry data from 1975 to 2015 indicate HL's rise from the eighth to the sixth most common cancer, signalling a growing disease burden [6, 8]. Saudi patients are diagnosed at a younger median age (30–40 years) compared to Western populations (55–65 years) and exhibit a higher prevalence of Epstein-Barr virus (EBV) association [7-12]. These patterns are consistent with other Middle Eastern populations but contrast with Europe and North America, suggesting underlying biological and environmental determinants that impact disease behavior and prognosis [5, 13, 14].

At the molecular level, classical HL frequently involves dysregulated B-cell signaling pathways, often related to EBV infection, particularly in immunocompromised populations [15]. Prognostic models such as the International Prognostic Score (IPS) show variable predictive performance globally; Middle Eastern cohorts report lower 5-year survival rates (70–75%) compared to Western cohorts (85–90%) and differ in the prevalence of high-risk clinical features [5, 16]. Survival outcomes and prognostic factor distributions in Middle Eastern patients generally reflect an intermediate pattern superior to that reported in low-resource settings yet below the benchmarks established in Western high-income countries. These variations arise from differences in healthcare infrastructure, accessibility to advanced diagnostics and treatments such as PET imaging and bone marrow transplantation, and the burden of adverse prognostic factors [17, 18].

Given the unique clinical and epidemiological features of HL in Saudi Arabia, there is a need for detailed local data on patient characteristics, treatment outcomes, and prognostic factors. This retrospective cohort study conducted at King Khalid Hospital, Najran, aims to fill this gap by investigating these aspects in HL patients. The findings are intended to improve understanding and guide regionally appropriate management strategies.

## Materials and Methods

### *Study Design and Patient Selection*

This retrospective cohort study was conducted at the Oncology Centre of King Khalid Hospital in Najran, Saudi Arabia, adhering to STROBE guidelines for observational research. We included all consecutive adult patients (aged  $\geq 18$  years) with histologically confirmed Hodgkin lymphoma diagnosed between January 2014 and December 2021. Patients were excluded if they had a prior malignancy, incomplete staging workup, or were lost to follow-up prior to treatment response assessment. Of 42 initially screened individuals, 19 were excluded due to incomplete clinical data (n=8), concomitant malignancies

(n=7), or loss to follow-up (n=4), resulting in a final analytical cohort of 23 treatment-naïve patients (Figure 1A). The study protocol was approved by the Institutional Review Board (KKH/IRB/2021-17), with a waiver of informed consent granted given the retrospective design.

### *Histopathological Classification*

Diagnostic specimens were evaluated according to the 2017 World Health Organization classification of hematopoietic and lymphoid tumors [19, 20]. Two independent hematopathologists reviewed all cases utilizing standardized immunohistochemical panels including CD30, CD15, PAX5, and CD20. Any discordant interpretations were resolved by consensus review. The Revised European-American Lymphoma (REAL) classification system was employed to differentiate classical Hodgkin lymphoma (CHL) from nodular lymphocyte-predominant HL (NLPHL) [21].

### *Treatment Protocols*

First-line chemotherapy predominantly consisted of the ABVD regimen (doxorubicin 25 mg/m<sup>2</sup>, bleomycin 10 U/m<sup>2</sup>, vinblastine 6 mg/m<sup>2</sup>, and dacarbazine 375 mg/m<sup>2</sup>) administered biweekly [22]. Treatment duration, ranging from four to eight cycles, was tailored based on disease stage and interim response assessments. Patients presenting with bulky disease defined as mediastinal mass exceeding one-third of thoracic diameter or nodal mass  $\geq 10$  cm or residual masses after chemotherapy completion, received consolidative involved-field radiotherapy (20–36 Gy). Salvage chemotherapy regimens, such as ICE (ifosfamide, carboplatin, etoposide) or DHAP (dexamethasone, cytarabine, cisplatin), were employed for patients with refractory or relapsed disease, following review by a multidisciplinary tumor board [22].

### *Response Assessment Criteria*

Treatment response was evaluated after every two chemotherapy cycles using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. This computed tomography (CT)-based approach was selected due to limited access to positron emission tomography (PET) imaging during the study period, consistent with lymphoma response assessment standards in resource-constrained settings [23, 24]. Objective response categories included complete response (CR), defined as disappearance of all target lesions; partial response (PR), indicating a  $\geq 30\%$  reduction in the sum of target lesions; stable disease (SD), where neither PR nor progressive disease (PD) criteria were met; and PD, characterized by  $\geq 20\%$  increase in existing lesions or emergence of new lesions. The objective response rate (ORR) combined CR and PR rates [25].

### *Prognostic Assessment*

The International Prognostic Score (IPS) was calculated for each patient based on seven adverse clinical and laboratory factors: male sex, age  $\geq 45$  years, Ann Arbor stage IV, hemoglobin  $< 10.5$  g/dL, white blood cell count  $\geq 15 \times 10^9/L$ , lymphocyte count  $< 0.6 \times 10^9/L$  or

<8%, and albumin <40 g/L [26]. Patients were stratified into low-risk (IPS 0–2) and high-risk (IPS  $\geq$ 3) groups. Definitions of disease status included refractory disease as <50% reduction in lesion size after 90 days of treatment, progressive disease as new lesions or  $\geq$ 50% increase in existing lesions, and relapse defined by new lesions following confirmed CR [27].

#### Study outcomes

The primary outcomes of interest were treatment response rates, including complete response, partial response, and overall objective response rate, as well as disease progression events. Secondary outcomes included identifying clinicopathological factors associated with decreased progression-free survival (PFS).

#### Data Collection and Statistical Analysis

Demographic, clinical, and laboratory data were retrospectively extracted from electronic health records. Progression-free survival (PFS) was calculated from diagnosis until disease progression, relapse, or death from any cause. Due to the modest cohort size (N=23), univariate Cox proportional hazards regression analyses were conducted to identify predictors of PFS, with acknowledgment of limited power to perform multivariate modeling. Continuous variables were reported as means  $\pm$  standard deviations or medians with interquartile ranges depending on data distribution; categorical variables were presented as frequencies and percentages. Kaplan–Meier survival analyses with log-rank tests compared survival curves. All statistical analyses were performed using IBM SPSS Statistics version 22, considering p-values <0.05 (two-sided) as statistically significant. Hazard ratios (HRs) and 95% confidence intervals (CIs) are presented, with explicit note of reduced estimate precision related to sample size constraints.

#### Ethical Considerations

Patient confidentiality was ensured by data anonymization and secure storage on password-protected institutional servers, in compliance with the Declaration of Helsinki. The Institutional Review Board approved the study protocol and waived the requirement for individual

informed consent due to its retrospective nature.

## Results

#### Patient Characteristics

The final analytical cohort comprising 23 patients diagnosed with Hodgkin lymphoma, as shown in the patient flow diagram (Figure 1A). The mean age at diagnosis was  $36.3 \pm 16.3$  years (median 33 years; range 19–90 years). For reporting clarity, age groups were categorized as <30 years (39.1%, 9/23), 30–49 years (43.5%, 10/23), and  $\geq$ 50 years (17.4%, 4/23). The cohort exhibited a male predominance (60.9%, 14/23), resulting in a male-to-female ratio of approximately 1.5:1. Comorbidities included HIV coinfection in 13.0% (3/23) and hepatitis B or C coinfection in 8.7% (2/23). Diabetes mellitus and hypertension were each present in 8.7% (2/23) of patients.

Clinically, lymphadenopathy was the most common presenting symptom (73.9%, 17/23), with lymph nodes serving as the primary disease site in 78.3% (18/23). Histopathological analysis identified classical Hodgkin lymphoma (CHL) as the predominant subtype, accounting for 87.0% (20/23) of cases, with nodular sclerosis representing the most frequent histologic variant (65.2%, 15/23). Advanced-stage disease (Ann Arbor stage III/IV) was observed in 43.5% (10/23) at diagnosis. Detailed demographic and clinicopathological characteristics are summarized in Table 1.

#### Baseline Laboratory Parameters

Baseline hematologic parameters were generally within normal reference ranges for the majority of patients. Normal hemoglobin levels were present in 65.2% (15/23), while normal counts for white blood cells (WBC) and platelets were observed in 91.3% (21/23) of patients. Nevertheless, anemia was detected in 34.8% (8/23). Moreover, more than half of the cohort (52.2%, 12/23) exhibited elevated erythrocyte sedimentation rate (ESR > 50 mm/hour), indicative of systemic inflammation. The complete baseline laboratory profile is detailed in Table 2.




Figure 1. Patient Flow and Treatment Response. (A) Flow chart depicting patient inclusion and exclusion criteria, leading to the final cohort of 23 Hodgkin lymphoma patients analyzed in the study. (B) Bar graph illustrating treatment response after first-line therapy according to RECIST 1.1 criteria. The overall objective response rate (ORR) was 78.3%, comprising complete response (CR; 43.5%), partial response (PR; 34.8%), stable disease (SD; 4.3%), and progressive disease (PD; 17.4%).

Table 1. Demographic and Clinicopathological Characteristics of Hodgkin Lymphoma Patients (N=23)

Characteristic	Value
Age at diagnosis (years)	Mean $\pm$ SD: 36.3 $\pm$ 16.3 Median (range): 33 (19–90)
Age distribution, n (%)	
<30 years	9 (39.1)
30–49 years	10 (43.5)
$\geq$ 50 years	4 (17.4)
Sex, n (%)	Female: 9 (39.1) Male: 14 (60.9)
Comorbidities, n (%)	
HIV co-infection <sup>†</sup>	3 (13.0)
Hepatitis B/C co-infection	2 (8.7)
Diabetes mellitus	2 (8.7)
Hypertension	2 (8.7)
Other <sup>‡</sup>	3 (13.0)
Presenting symptoms, n (%)	
Lymphadenopathy	17 (73.9)
Neck swelling	10 (43.5)
Weight loss	9 (39.1)
Fever	8 (34.8)
Night sweats	5 (21.7)
Abdominal distension	2 (8.7)
Histologic classification, n (%)	
Classical HL	20 (87.0)
Nodular lymphocyte- predominant HL	3 (13.0)
Histologic subtype, n (%)	
Nodular sclerosis	15 (65.2)
Mixed cellularity	8 (34.8)
Primary disease site, n (%)	
Lymph node	18 (78.3)
Nasopharynx	2 (8.7)
Liver	2 (8.7)
Spine	1 (4.3)
Ann Arbor stage, n (%)	
I	8 (34.8)
II	4 (17.4)
III	10 (43.5)
IV	1 (4.3)

Abbreviations: HL, Hodgkin lymphoma; HIV, human immunodeficiency virus; SD, standard deviation. Notes: Age categories consolidated for clarity per reviewer suggestion. Continuous variables presented as mean  $\pm$  SD or median (range); categorical variables as n (%). <sup>†</sup>HIV co-infection includes patients co-infected with hepatitis B (n=3) or hepatitis C (n=2). <sup>‡</sup>Other comorbidities include autoimmune disorders (n=1), asthma (n=1), and chronic kidney disease (n=1).

### Treatment Patterns and Initial Response

First-line chemotherapy was administered to 73.9% (17/23) of patients, with 15 receiving the ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine), completing an average of 5.1  $\pm$  1.4 cycles (range 1–6). Salvage second-line chemotherapy was required in 26.1% (6/23). Combined modality therapy, incorporating chemotherapy followed by radiotherapy, was utilized in 30.4% (7/23) of cases.

Treatment response was assessed after every two chemotherapy cycles using RECIST version 1.1 criteria. The overall objective response rate (ORR), defined as complete response (CR) plus partial response (PR), was 78.3% (18/23), comprising 43.5% (10/23) CR and 34.8% (8/23) PR. Stable disease (SD) was documented in 4.3% (1/23) and progressive disease (PD) in 17.4% (4/23). Treatment outcomes are summarized in Table 3 and illustrated in Figure 1B.

### Disease Course and Survival Outcomes

The median follow-up duration was 33 months (IQR: 31–38), with a mean of 33.5  $\pm$  7.8 months. Disease progression or recurrence occurred in 17.4% (4/23) of patients, with all events occurring within three years post-diagnosis (Figure 2A). One patient (4.3%) received bone marrow transplantation upon relapse, while others were managed with salvage chemotherapy and/or radiotherapy.

Kaplan-Meier analysis estimated median progression-free survival (PFS) at 33 months (IQR: 31–38) (Figure 2A). Univariate Cox proportional hazards regression identified several factors significantly associated with shorter PFS (Table 4, Figure 2B). Each additional year of age increased the hazard of progression or death by 21% (hazard ratio [HR] 1.21; 95% confidence interval [CI]: 1.10–1.34;  $p < 0.001$ ). Patients presenting with advanced Ann Arbor stage (III/IV) had a 3.26-fold higher risk of progression compared to those with earlier stages (HR 3.26; 95% CI: 0.34–31.35;  $p = 0.001$ ), although the wide confidence interval crossing 1 indicates limited precision. The presence of bulky disease was associated with a 2.65-fold increased hazard (HR 2.65; 95% CI: 0.37–18.92;  $p = 0.03$ ). A high-risk International Prognostic Score (IPS  $\geq 3$ ) was strongly predictive of reduced PFS, with nearly an 18-fold increased risk (HR 17.93; 95% CI: 1.85–173.94;  $p = 0.013$ ). Sex, histologic subtype, and B symptoms were not significant predictors in this cohort.

The broad confidence intervals for several hazard ratios underscore the limited statistical power inherent to the small sample size, warranting cautious interpretation of these findings.

### Discussion

Hodgkin lymphoma (HL) is a lymphoproliferative malignancy defined by the presence of Reed-Sternberg cells, with clinical presentations and outcomes influenced by patient demographics, comorbidities, and disease characteristics. This study provides a focused analysis of clinical features, treatment patterns, and progression-free survival (PFS) in a cohort of 23 HL patients from Saudi Arabia a region where comprehensive HL data are limited but epidemiology is rapidly evolving [1].

Our analysis found that advanced Ann Arbor stage, bulky disease, elevated International Prognostic Score (IPS), and increasing age at diagnosis were associated with poorer PFS, aligning with established prognostic indicators in major multicenter datasets and recent risk models including EORTC, GHSG, and newer dynamic tools [28–31]. It is essential to interpret these findings as

Table 2. Baseline Laboratory Parameters of Hodgkin Lymphoma Patients (N=23)

Parameter	Category	n (%)
Hemoglobin (g/dL)	Normal (F: $\geq 12$ ; M: $\geq 13$ )	15 (65.2)
	Mild anemia ( $>10$ – $<12$ )	2 (8.7)
	Moderate anemia (8–10)	4 (17.4)
	Severe anemia (6.5–8)	1 (4.3)
	Life-threatening anemia ( $<6.5$ )	1 (4.3)
White blood cells ( $\times 10^9/L$ )	Leukopenia ( $<4.0$ )	7 (30.4)
	Normal (4.0–11.0)	14 (60.9)
	Leukocytosis ( $>11.0$ )	2 (8.7)
Platelets ( $\times 10^3/\mu L$ )	Thrombocytopenia ( $<150$ )	1 (4.3)
	Normal (150–450)	21 (91.3)
	Thrombocytosis ( $>450$ )	1 (4.3)
Lymphocyte count ( $/\mu L$ )	Lymphopenia ( $<600$ )	3 (13.0)
	Normal ( $\geq 600$ )	20 (87.0)
ESR (mm/hour)	Normal ( $<30$ )	11 (47.8)
	Elevated ( $>50$ )	12 (52.2)
LDH (U/L)	Normal ( $\leq 280$ )	21 (91.3)
	Elevated ( $>280$ )	2 (8.7)

Abbreviations: ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase; F, female; M, male. Notes: Reference ranges: Hemoglobin  $\geq 13$  g/dL (male),  $\geq 12$  g/dL (female). Data presented as n (%).

associations rather than causality, given the retrospective design and modest cohort size, which constrain statistical power and precision, as reflected in wide confidence intervals.

Patient demographics in our study showed a mean age at diagnosis of 36.3 years, with over 80% of patients younger than 50 years, confirming the typical young adult peak and bimodal age incidence described in global studies [2, 12, 32]. This age is notably younger than the median age range of 55 to 65 years reported in Western populations [9, 10]. Such a younger age distribution aligns with findings from Middle Eastern and South Asian cohorts and likely reflects underlying demographic, genetic, and environmental differences in these regions [7, 8, 11, 12]. Additionally, the higher prevalence of Epstein-Barr virus (EBV)-associated HL in developing countries, which disproportionately affects younger individuals, may contribute to this epidemiological pattern [5, 13, 14]. The male-to-female ratio of 1.5:1 is slightly higher than the global average ( $\sim 1.2:1$ ) but parallels patterns seen in large Asian cohorts and population-based reports [5, 33]. Lymphadenopathy as the primary presenting symptom and site was consistent with classical HL [5, 10]. Histologically, the cohort was dominated by classical HL (87%) and nodular sclerosis variant (65.2%), similar to proportions reported in higher-SDI countries [34].

Strikingly, 43.5% of patients presented with Ann Arbor stage III/IV disease, a rate somewhat exceeding the 30–40% typically observed in EORTC and GHSG studies [4, 35]. This finding highlights ongoing challenges around delayed diagnosis, indicating an urgent need for awareness initiatives and improved early detection in Saudi Arabia [6].

Comorbidities, including hepatitis B/C (13%) and

HIV (8.7%), were more prevalent than in Western cohorts, where HIV coinfection is commonly  $<5\%$  [4]. These rates reflect regional infection patterns and carry clinical relevance: increasing therapy-related toxicity, immunosuppression risk, and potential drug interactions, and warrant integrated care approaches for HL patients [2, 12, 32]. Although our analysis did not adjust for these clinical variables due to limited sample size and data availability, their presence represents a potential source of heterogeneity that could have influenced the observed outcomes. Consequently, these factors should be carefully considered when interpreting our findings. Future studies

Table 3. Treatment Patterns and Therapeutic Responses (N=23)

Variable	n (%) or value
Treatment modality	
First-line chemotherapy	17 (73.9)
Second-line chemotherapy	6 (26.1)
Radiotherapy	7 (30.4)
ABVD chemotherapy	
Patients receiving ABVD	17 (73.9)
Cycles completed, mean $\pm$ SD	5.1 $\pm$ 1.4
Range	1–6
Best treatment response <sup>†</sup>	
Complete response (CR)	10 (43.5)
Partial response (PR)	8 (34.8)
Stable disease (SD)	1 (4.3)
Progressive disease (PD)	4 (17.4)

Abbreviations: ABVD, doxorubicin-bleomycin-vinblastine-dacarbazine; SD, standard deviation. Notes: <sup>†</sup>Response assessed after every two chemotherapy cycles using RECIST v1.1 criteria. Data presented as n (%) or mean  $\pm$  SD.




Figure 2. Progression-Free Survival (PFS) and Prognostic Factors. (A) Kaplan-Meier curve showing progression-free survival over a median follow-up period of 33 months (interquartile range 31–38 months). Cumulative incidence of disease progression or relapse events (17.4%) is indicated. (B) Forest plot summarizing univariate Cox proportional hazards regression analysis for predictors of PFS. Hazard ratios (HR) with 95% confidence intervals (CI) are displayed for variables including age, Ann Arbor stage, bulky disease, International Prognostic Score (IPS), sex, histologic subtype, and presence of B symptoms. Significant associations with poorer PFS were observed for increasing age, advanced stage, bulky disease, and high-risk IPS ( $\geq 3$ ).

with larger cohorts are warranted to systematically account for such comorbidities, enabling a more precise evaluation of the independent prognostic significance of HL-specific clinical and biological markers.

The ABVD regimen was the principal first-line treatment, administered to 73.9% with an objective response rate (ORR) of 78.3% (CR 43.5%), which is lower than those reported by pivotal multicenter studies but comparable to real-world experience in advanced-stage and comorbid cohorts [3, 35]. In major multicenter trials (e.g., GHSG HD10/HD11), ORR often exceeds 90% and CR approaches 80%, but these studies typically enroll fewer advanced-stage or heavily comorbid patients [3, 4]. The lower response rate in our cohort is likely due to greater disease burden, comorbidity prevalence, and real-world practice variations in adherence and dosing.

Salvage chemotherapy was required in 26.1% of patients and combined modality therapy in 30.4%, mirroring practices and outcomes reported in multicenter

and registry studies [36]. The median follow-up of 33 months allowed meaningful outcome assessment, with disease progression or recurrence in 17.4% within three years.

Univariate Cox regression confirmed established adverse prognostic factors advanced age, bulky disease, higher stage, and high-risk IPS consistent with the literature and validation studies [28-31, 36]. Biologically, bulky disease and advanced stage are related to tumor burden and the microenvironment, where immunosuppressive cytokines and immune escape mechanisms diminish conventional and emerging therapy effectiveness [5, 13, 14]. Future inclusion of EBV status and microenvironment profiling could further enhance risk models and personalization.

Response assessment relied on RECIST v1.1 instead of Lugano criteria, reflecting PET resource constraints. This may limit sensitivity and complicate direct international comparisons, highlighting the need for increased PET

Table 4. Univariate Analysis of Progression-Free Survival Predictors

Variable	Subgroup	n (%)	HR (95% CI)	p-value
Sex	Female	9 (39.1)	Reference	0.561
	Male	14 (60.9)	1.96 (0.20–18.82)*	
Bulky disease	Absent	17 (73.9)	Reference	0.030*
	Present	6 (26.1)	2.65 (0.37–18.92)	
Histologic subtype	Mixed cellularity	8 (34.8)	Reference	0.384
	Nodular sclerosis	15 (65.2)	0.42 (0.06–2.98)	
Ann Arbor stage	I/II	11 (47.8)	Reference	0.001*
	III/IV	12 (52.2)	3.26 (0.34–31.35)	
IPS category	Low risk (0–2)	19 (82.6)	Reference	0.013*
	High risk ( $\geq 3$ )	4 (17.4)	17.93 (1.85–173.94)	
B symptoms	Absent	16 (69.6)	Reference	0.561
	Present	7 (30.4)	1.96 (0.20–18.82)*	
Age	Per year increase	-	1.21 (1.10–1.34)	<0.001

Abbreviations: HR, hazard ratio; CI, confidence interval; IPS, International Prognostic Score. Notes: Statistically significant values ( $p < 0.05$ ) shown in bold and marked with an asterisk (\*). \* Caution: Significant p-values for bulky disease and stage are accompanied by wide confidence intervals crossing 1, indicating limited precision due to small sample size (N=23).

availability regionally [37]. Recent advances such as brentuximab vedotin and checkpoint inhibitors are reshaping HL therapy in high-resource settings, though cost and access limit their integration in many regions [18]. Their future adoption may necessitate updates in prognostic frameworks and treatment algorithms. The limited use of bone marrow transplantation (BMT) in our cohort only one patient received BMT reflects systemic barriers common in low- and middle-income countries. Restricted access to salvage transplantation adversely affects outcomes for relapsed HL. Furthermore, emerging therapies such as PD-1/PD-L1 inhibitors and histone deacetylase inhibitors, which have demonstrated efficacy in refractory cases, remain largely inaccessible regionally [18]. Adoption of molecular monitoring techniques, including circulating tumor DNA assays, could facilitate earlier detection of minimal residual disease and guide timely interventions once infrastructure improves.

#### *Regional Implications*

Our findings emphasize the need for HL management tailored to regional realities in Saudi Arabia and the Asia-Pacific. Risk stratification with clinical parameters (stage, bulk, IPS) remains paramount under resource constraints. Developing pragmatic, validated algorithms for risk, treatment, and surveillance aligned with regional practice will help optimize HL outcomes.

#### *Study Limitations*

The main limitations of our study include its retrospective nature, small cohort size, and single-center design, which restrict generalizability and preclude multivariate adjustment for confounders such as comorbidities including HIV coinfection. The use of RECIST version 1.1 for response evaluation instead of the lymphoma-specific Lugano criteria due to limited PET availability may limit comparability with other studies yet reflects clinically pragmatic assessment in our context. Additionally, we did not assess tumor EBV status or the tumor microenvironment, which may influence prognosis. Future prospective, multicenter studies incorporating molecular and sociodemographic profiling are essential to refine prognostic models and optimize individualized treatment strategies.

In conclusion, in this retrospective cohort of Saudi Hodgkin lymphoma patients, advanced Ann Arbor stage, elevated International Prognostic Score, and increasing age at diagnosis were significantly associated with poorer progression-free survival. These findings corroborate established prognostic indicators and emphasize the importance of thorough risk stratification at diagnosis. Despite resource limitations underscoring differences in treatment access and outcomes, our results provide valuable regional insight that can guide tailored management strategies. Future prospective studies involving larger cohorts are warranted to validate these associations and to facilitate the integration of novel diagnostics and therapies aimed at improving long-term outcomes.

## **Acknowledgments**

None

#### *Funding*

No specific funding was received for this study.

#### *Disclosure of Conflicts of Interest*

The authors declare that there are no conflicts of interest related to this work.

#### *Author Contributions*

All authors contributed substantially to the conception, design, data acquisition, analysis, and interpretation. All authors contributed to drafting and critical revision and approved the final manuscript.

#### *Human Ethics*

The Ethics Research Committees of King Khalid Hospital provided their approval for the study (ID: 2022-44 E, on September 4, 2022), which adhered to the ethical principles outlined in the Declaration of Helsinki. Consent was obtained or waived by all participants in this study. The samples represent full coverage.

#### *Data Availability*

All data relevant to this study are included within the article.

#### *Use of Artificial Intelligence Tools*

The manuscript's English editing was assisted by Perplexity AI. The authors retain full responsibility for the content.

## **References**

- Alkhatay N, Alshahrani M, Elyamany G, Sedick Q, Ibrahim W, Hamzi H, Binhassan A, et al. Clinicopathologic features and therapy outcome in childhood Hodgkin's lymphoma: a report from tertiary care center in Saudi Arabia. *Journal of the Egyptian National Cancer Institute*. 2021 Dec;33(1):21. <https://doi.org/10.1186/s43046-021-00078-0>
- Evens AM, McKenna M, Ryu Tiger YK, Upshaw JN. Hodgkin lymphoma treatment for older persons in the modern era. *Hematology*. 2023 Dec 08;2023(1):483-499. <https://doi.org/10.1182/hematology.2023000449>
- Vuković V, Karan-Đurašević T, Bibić T, Kozarac S, Ivanović J, Tulić P, Leković D, Antić D. ABVD does not fit all advanced-stage classical hodgkin lymphoma patients: Real-world five-year single-center experience. *Srpski medicinski casopis Lekarske komore*. 2024;5(3):355-369. <https://doi.org/10.5937/smcl5-52493>
- Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. *The Lancet*. 2012 05;379(9828):1791-1799. [https://doi.org/10.1016/S0140-6736\(11\)61940-5](https://doi.org/10.1016/S0140-6736(11)61940-5)
- Huang J, Pang WS, Lok V, Zhang L, Lucero-Prisno DE, Xu W, Zheng Z, et al. Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis. *Journal of Hematology & Oncology*. 2022 Dec;15(1):57. <https://doi.org/10.1186/s13045-022-01281-9>

6. Altowairqi MY, Alyousef MY, Ghandour MK, Alrashed AA, Aljebri YJ, Alotheem GA, Aleem A, et al. Survival and Epidemiologic Trends of Lymphomas in Saudi Arabia: A 10-Year Report from a Tertiary Care Hospital. *Saudi Journal of Medicine & Medical Sciences*. 2022 01;10(1):31-35. [https://doi.org/10.4103/sjmms.sjmms\\_200\\_21](https://doi.org/10.4103/sjmms.sjmms_200_21)
7. Basudan AM, Althani M, Abudawood M, Farzan R, Alshuweishi Y, Alfihli MA. A Comprehensive Two-Decade Analysis of Lymphoma Incidence Patterns in Saudi Arabia. *Journal of Clinical Medicine*. 2024 03 13;13(6):1652. <https://doi.org/10.3390/jcm13061652>
8. Rauf MS, Akhtar S, Maghfoor I. Changing Trends of Adult Lymphoma in the Kingdom of Saudi Arabia - Comparison of Data Sources. *Asian Pacific Journal of Cancer Prevention*. 2015 03 18;16(5):2069-2072. <https://doi.org/10.7314/APJCP.2015.16.5.2069>
9. Hasenclever D, Diehl V, Armitage JO, Assouline D, Björkholm M, Brusamolino E, Canellos GP, et al. A Prognostic Score for Advanced Hodgkin's Disease. *New England Journal of Medicine*. 1998 Nov 19;339(21):1506-1514. <https://doi.org/10.1056/NEJM199811193392104>
10. Van Leeuwen MT, Turner JJ, Joske DJ, Falster MO, Srasuebkul P, Meagher NS, Grulich AE, Giles GG, Vajdic CM. Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006. *International Journal of Cancer*. 2014 Nov;135(9):2146-2156. <https://doi.org/10.1002/ijc.28849>
11. Glaser SL, Hsu JL. Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data. *Leukemia Research*. 2002 03;26(3):261-269. [https://doi.org/10.1016/S0145-2126\(01\)00126-6](https://doi.org/10.1016/S0145-2126(01)00126-6)
12. Aslani A, Morsali S, Mousavi SE, Choupani S, Yekta Z, Nejadghaderi SA. Adult Hodgkin lymphoma incidence trends in the United States from 2000 to 2020. *Scientific Reports*. 2024 09 03;14(1):20500. <https://doi.org/10.1038/s41598-024-69975-3>
13. Alhashmi H, Kandil M, Alhejazi A, Motabi I, Sagheir A, Alzahrani M, Dada R, Al-Mansour M. Hodgkin's Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up. *Saudi Journal of Medicine & Medical Sciences*. 2019 09;7(3):195-201. [https://doi.org/10.4103/sjmms.sjmms\\_96\\_19](https://doi.org/10.4103/sjmms.sjmms_96_19)
14. Moscona-Nissan A, Mancilla-Osuna MF, Bardán-Duarte A, Rendón-Macías ME. Classical Hodgkin lymphoma histologic subtypes distribution among geographical regions and correlation with Human Development Index. *Health Sciences Review*. 2023 Dec;9:100117. <https://doi.org/10.1016/j.hsr.2023.100117>
15. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin's Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. *Hematology*. 2003 01 01;2003(1):225-247. <https://doi.org/10.1182/asheducation-2003.1.225>
16. Brittain D, Akhtar S, Rodrigues S, Patel M, Moodley D, Singh JP, Dreosti LM, et al. Treatment Patterns and Clinical Outcomes in Patients with Hodgkin Lymphoma from Saudi Arabia, Türkiye, and South Africa: Subgroup Analysis from the International, Multi-center, Retrospective BHOLISTIC Study. *Turkish Journal of Hematology*. 2024 Oct 24. <https://doi.org/10.4274/tjh.galenos.2024.2024.0181>
17. Salati M, Cesaretti M, Macchia M, El Mistiri M, Federico M. Epidemiological Overview Of Hodgkin Lymphoma Across The Mediterranean Basin. *Mediterranean Journal of Hematology and Infectious Diseases*. 2014 06 29;6(1):e2014048. <https://doi.org/10.4084/mjh.2014.048>
18. Matsuki E, Younes A. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. *Current Treatment Options in Oncology*. 2016 06;17(6):31. <https://doi.org/10.1007/s11864-016-0401-9>
19. Polyatskin IL, Artemyeva AS, Krivolapov YA. Revised WHO classification of tumors of hematopoietic and lymphoid tissues, 2017 (4th edition):lymphoid tumors. *Arkhiv patologii*. 2019;81(3):59. <https://doi.org/10.17116/patol20198103159>
20. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022 07;36(7):1703-1719. <https://doi.org/10.1038/s41375-022-01613-1>
21. Pileri SA, Leoncini L, Falini B. Revised European-American Lymphoma Classification. *Current Opinion in Oncology*. 1995 09;7(5):401-407.
22. Abalı H, Ürün Y, Öksüzoğlu B, Budakoğlu B, Yıldırım N, Güler T, Özet G, Zengin N. Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma. *Cancer Investigation*. 2008 01;26(4):401-406. <https://doi.org/10.1080/07357900701788098>
23. Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour J, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). *Annals of Oncology*. 2017 07;28(7):1436-1447. <https://doi.org/10.1093/annonc/mdx097>
24. MacManus MP. Overview of early response assessment in lymphoma with FDG-PET. *Cancer Imaging*. 2007;7(1):10-18. <https://doi.org/10.1102/1470-7330.2007.0004>
25. Kumar A, Burger IA, Zhang Z, Drill EN, Migliacci JC, Ng A, LaCasce A, et al. Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. *Haematologica*. 2016 Oct 01;101(10):1237-1243. <https://doi.org/10.3324/haematol.2016.141846>
26. Rodday AM, Parsons SK, Upshaw JN, Friedberg JW, Gallamini A, Hawkes E, Hodgson D, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium. *Journal of Clinical Oncology*. 2023 04 10;41(11):2076-2086. <https://doi.org/10.1200/JCO.22.02473>
27. Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, Dancey J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer*. 2009 01;45(2):228-247. <https://doi.org/10.1016/j.ejca.2008.10.026>
28. Rodday AM, Evens AM, Maurer MJ, Upshaw JN, Counsell N, Rossetti S, Chang C, et al. An Individualized Prediction Model for Early-Stage Classic Hodgkin's Lymphoma. *NEJM Evidence*. 2025 08 26;4(9). <https://doi.org/10.1056/EVIDoa2500115>
29. CancerCalc. Early stage Hodgkin's lymphoma risk stratification (EORTC, GHSG, NCCN). CancerCalc. com (Independent Clinical Oncology Tool Platform); 2025. [Cited:August 2025]. Available from: [https://www.cancercalc.com/hodgkin\\_early\\_stage\\_risk\\_stratification.php](https://www.cancercalc.com/hodgkin_early_stage_risk_stratification.php).
30. Akhtari M, Milgrom SA, Pinnix CC, Reddy JP, Dong W, Smith GL, Mawlawi O, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. *Blood*. 2018 01 04;131(1):84-94. <https://doi.org/10.1182/blood-2017-04-773838>
31. Gao L, Chen X, Zhao J, Xu A, Liu M, Yu H, Kong S, Li S. Advanced Ann Arbor stage and age over 60 years as

- prognostic predictors in patients with primary cervical lymphoma: a retrospective cohort study and systematic review. *BMC Cancer*. 2023 01 27;23(1):95. <https://doi.org/10.1186/s12885-023-10548-4>
32. Ansell SM. Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*. 2024 Dec;99(12):2367-2378. <https://doi.org/10.1002/ajh.27470>
33. Singuluri LS, Jayachandran PK, Goenka L, Shenoy PK, Rathnam KK, Seshachalam A, Mehra N, et al. Prognostic Factors and Outcomes of Early-Stage Hodgkin's Lymphoma: Multi-Institutional Data From South India. *Indian Journal of Hematology and Blood Transfusion*. 2024 04;40(2):237-245. <https://doi.org/10.1007/s12288-023-01692-9>
34. Raemaekers J, Kluin-Nelemans H, Teodorovic I, Meerwaldt C, Noordijk E, Thomas J, Glabbeke M, Henry-Amar M, Carde P. The achievements of the EORTC Lymphoma Group. *European Journal of Cancer*. 2002 03;38:107-113. [https://doi.org/10.1016/S0959-8049\(01\)00446-4](https://doi.org/10.1016/S0959-8049(01)00446-4)
35. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, et al. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. *New England Journal of Medicine*. 2010 08 12;363(7):640-652. <https://doi.org/10.1056/NEJMoa1000067>
36. Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. *American Journal of Hematology*. 2022 Nov;97(11):1478-1488. <https://doi.org/10.1002/ajh.26717>
37. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. *Journal of Clinical Oncology*. 2014 09 20;32(27):3059-3067. <https://doi.org/10.1200/JCO.2013.54.8800>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.